

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE**  
**Recommendations Summary**  
**May 11, 2011**

**In Attendance:**

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	Catherine Decker PharmD	Yes
3	Bradley Fedderly M.D.	Yes
4	Lawrence Fleming M.D.	No
5	Al Liegel, RPh	Yes
6	Kevin Izard M.D.	Yes
7	Steve Maike RPh	No
8	Pat Towers	Yes
9	Alicia Walker PharmD	Yes
10	Michael Witkovsky M.D.	No
11	James Boblin M.D.	Yes
12	Ward Brown, M.D.	No
13	Anthony DeFranco M.D., FACC	No
14	Ronald Diamond, M.D.	Present 12:00-12:45pm / returned to session at 2:50pm

ANALGESICS, NARCOTICS LONG  
ANALGESICS, NARCOTICS SHORT  
SKELETAL MUSCLE RELAXANTS  
ANTIMIGRAINE AGENTS  
ANTIEMETICS/ANTIVERTIGO AGENTS  
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS  
HYPOGLYCEMICS, INSULIN  
HYPOGLYCEMICS, MEGLITINIDES  
HYPOGLYCEMICS, TZD  
MULTIPLE SCLEROSIS AGENTS  
LIPOTROPICS, OTHER  
LIPOTROPICS, STATINS  
PLATELET AGGREGATION INHIBITORS  
ANTICOAGULANTS  
ANDROGENIC AGENTS  
BPH TREATMENTS  
PAH AGENTS  
BLADDER RELAXANT PREPARATIONS  
BETA-BLOCKERS  
CALCIUM CHANNEL BLOCKERS  
ANGIOTENSIN MODULATOR COMBINATIONS  
ANGIOTENSIN MODULATORS  
PROTON PUMP INHIBITORS  
ACNE AGENTS, TOPICAL  
ANTIBIOTICS, GI  
ANTIBIOTICS, INHALED  
ANTIBIOTICS, TOPICAL  
ANTIBIOTICS, VAGINAL  
CEPHALOSPORINS AND RELATED ANTIBIOTICS  
FLUOROQUINOLONES, ORAL  
MACROLIDES/KETOLIDES  
TETRACYCLINES, ORAL  
ANTIFUNGALS, ORAL  
ANTIFUNGALS, TOPICAL  
ANTIVIRALS, ORAL  
ANTIVIRALS, TOPICAL  
ANTIPARASITICS, TOPICAL  
BONE RESORPTION SUPPRESSION AND RELATED AGENTS  
COLONY STIMULATING FACTORS  
ERYTHROPOIESIS STIMULATING PROTEINS  
GROWTH HORMONE  
HEPATITIS C AGENTS  
ULCERATIVE COLITIS AGENTS  
PANCREATIC ENZYMES  
PHOSPHATE BINDERS  
HIV/AIDS

<b>ANALGESICS, NARCOTICS LONG</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
METHADONE (ORAL)	22.0%	ON	Yes-Generic			
MORPHINE ER (ORAL)	22.2%	ON	Yes-Generic			
KADIAN (ORAL)	2.6%	ON	Yes			
BUTRANS (TRANSDERM)	0.0%	OFF	No			
FENTANYL (TRANSDERM)	17.9%	ON	Yes-Generic			
OPANA ER (ORAL)	0.8%	OFF	No			
RYZOLT (ORAL)	0.0%	OFF	No			
TRAMADOL ER (ORAL)	0.5%	OFF	No-Generic			
EXALGO (ORAL)	0.0%	OFF	No			
EMBEDA (ORAL)	0.2%	OFF	No			
AVINZA (ORAL)	0.1%	OFF	No			
OXYCODONE ER (ORAL)	2.1%	OFF	No-Generic			
OXYCONTIN REFORMULATED (ORAL)	31.3%	ON	No			

- Discussion: Dr Izard would like to see another option to replace Oxycontin besides morphine and methadone. Committee stated there was abuse and abuse potential with Oxycontin.
- Embeda was voluntarily withdrawn from the market.
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second – James Boblin
  - The vote was 7-2 in favor of this motion. Kevin Izard and Alicia Walker were opposed.
  - Motion passes.

<b>ANALGESICS, NARCOTICS SHORT</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
TRAMADOL (ORAL)	13.0%	ON	Yes-Generic			
APAP / CODEINE (ORAL)	8.5%	ON	Yes-Generic			
HYDROCODONE / APAP (ORAL)	49.8%	ON	Yes-Generic			
MEPERIDINE (ORAL)	0.0%	OFF	No-Generic			
MORPHINE IR (ORAL)	0.8%	ON	Yes-Generic			
ZOLVIT (ORAL)	0.0%	OFF	No			
HYDROCODONE / IBUPROFEN (ORAL)	0.4%	ON	Yes-Generic			

OXYCODONE / APAP (ORAL)	18.6%	ON	Yes-Generic			
HYDROMORPHONE (ORAL)	0.6%	ON	Yes-Generic			
IBUDONE (ORAL)	0.0%	OFF	No			
TRAMADOL / APAP (ORAL)	0.0%	OFF	No-Generic			
BUTALBITAL COMPOUND W/CODEINE (ORAL)	0.1%	OFF	No-Generic			
CODEINE (ORAL)	0.1%	ON	Yes-Generic			
OXYCODONE (ORAL)	8.0%	ON	Yes-Generic			
OXYCODONE / IBUPROFEN (ORAL)	0.0%	ON	No-Generic			
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	0.0%	OFF	No-Generic			
PENTAZOCINE / APAP (ORAL)	0.0%	OFF	No-Generic			
PENTAZOCINE / NALOXONE (ORAL)	0.0%	OFF	No-Generic			
TREZIX (ORAL)	0.0%	OFF	No-Generic			
ZAMICET (ORAL)	0.0%	OFF	No			
OXYCODONE / ASA (ORAL)	0.0%	ON	No-Generic			
REPREXAIN (ORAL)	0.0%	OFF	No			
DILAUDID LIQUID (ORAL)	0.0%	OFF	No			
RYBIX ODT (ORAL)	0.0%	OFF	No			
LEVORPHANOL (ORAL)	0.0%	OFF	No-Generic			
NUCYNTA (ORAL)	0.1%	OFF	No			
OPANA (ORAL)	0.1%	OFF	No			
OXYMORPHONE (ORAL)	0.0%	OFF	No-Generic			
ABSTRAL (SUBLINGUAL)	0.0%	OFF	No			
FENTANYL (BUCCAL)	0.0%	OFF	No-Generic			
ONSOLIS (BUCCAL)	0.0%	OFF	No			
FENTORA (BUCCAL)	0.0%	OFF	No			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

SKELETAL MUSCLE RELAXANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CYCLOBENZAPRINE (ORAL)	65.5%	ON	Yes-Generic			
CHLORZOXAZONE (ORAL)	0.8%	ON	Yes-Generic			
CARISOPRODOL (ORAL)	2.6%	OFF	No-Generic			
BACLOFEN (ORAL)	12.5%	ON	Yes-Generic			

CARISOPRODOL COMPOUND (ORAL)	0.0%	OFF	No-Generic			
TIZANIDINE (ORAL)	10.5%	ON	Yes-Generic			
METHOCARBAMOL (ORAL)	5.6%	ON	Yes-Generic			
ORPHENADRINE (ORAL)	0.2%	OFF	No-Generic			
SOMA 250 MG (ORAL)	0.1%	OFF	No			
ORPHENADRINE COMPOUND (ORAL)	0.0%	OFF	No-Generic			
DANTROLENE SODIUM (ORAL)	0.4%	ON	Yes-Generic			
ZANAFLEX CAPSULES (ORAL)	0.0%	OFF	No			
AMRIX (ORAL)	0.1%	OFF	No			
METAXALONE (ORAL)	1.6%	ON	No-Generic			
FEXMID (ORAL)	0.0%	OFF	No			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second – Pat Towers
  - The vote was 7-1 in favor of the motion. Alicia Walker was opposed to the motion.
  - Motion passes

ANTIMIGRAINE AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SUMATRIPTAN (ORAL)	58.7%	ON	Yes-Generic			
MAXALT MLT (ORAL)	6.6%	ON	No			
RELPAX (ORAL)	9.2%	OFF	No			
AXERT (ORAL)	0.5%	OFF	No			
MAXALT TABLETS (ORAL)	12.2%	ON	No			
NARATRIPTAN (ORAL)	0.2%	OFF	Yes			
FROVA (ORAL)	0.7%	OFF	No			
TREXIMET (ORAL)	0.9%	OFF	No			
ZOMIG / ZOMIG ZMT (ORAL)	1.3%	OFF	No			
ZOMIG (NASAL)	0.2%	OFF	No			
SUMATRIPTAN (NASAL)	2.4%	ON	Yes-Generic			
CAMBIA (ORAL)	0.0%	OFF	No			
SUMATRIPTAN (SUBCUTANE.)	7.2%	ON	Yes-Generic			

- Discussion: Alicia Walker questioned if there is a difference between Maxalt and sumatriptan because people respond differently to migraine medications. Rick Pope stated that naratriptan can be considered longer acting, but when dosed correctly, they are supposed to be all equally efficacious.

Motion #1

- Alicia Walker made a motion to accept staff recommendations as presented, but grandfather members currently taking Maxalt and Maxalt MLT.
  - Second –Pat Towers
  - The vote was 2-6 in favor of this motion. Catherine Decker, Brad Fedderly, Kevin Izard, Roseanne Barber, Al Liegel and James Boblin were opposed.
  - Motion fails

Motion #2

- James Boblin made a motion to accept staff recommendations as presented.
  - Second-Brad Fedderly
  - The vote was 7-1 in favor of the motion. Alicia Walker was opposed.
  - Motion passes

ANTIEMETIC-ANTIVERTIGO AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PROCHLORPERAZINE (ORAL)	10.8%	ON	Yes-Generic			
MECLIZINE (ORAL)	11.7%	ON	Yes-Generic			
MOTION SICKNESS OTC (ORAL)	2.9%	NR	No-Generic			
METOCLOPRAMIDE (ORAL)	8.5%	NR	Yes-Generic			
PROMETHAZINE (ORAL)	11.2%	ON	Yes-Generic			
ONDANSETRON TABLETS (ORAL)	22.1%	ON	Yes-Generic			
ONDANSETRON ODT (ORAL)	23.4%	ON	Yes-Generic			
PROMETHAZINE (RECTAL)	1.5%	ON	Yes-Generic			
TRIMETHOBENZAMIDE (ORAL)	0.0%	OFF	Yes-Generic			
SCOPACE (ORAL)	0.1%	ON	Yes			
PROCHLORPERAZINE (RECTAL)	0.7%	ON	Yes-Generic			
TRANSDERM-SCOP (TRANSDERM)	2.9%	NR	Yes			
MARINOL (ORAL)	0.2%	ON	Yes			
METIZOLV ODT (ORAL)	0.0%	NR	No			
ONDANSETRON SOLUTION (ORAL)	2.4%	ON	Yes-Generic			
ZUPLENZ (ORAL)	0.0%	OFF	No			
ANZEMET (ORAL)	0.0%	OFF	No			
EMEND (ORAL)	1.1%	ON	Yes			
GRANISETRON (ORAL)	0.1%	OFF	No-Generic			
SANCUSO (TRANSDERMAL)	0.1%	ON	No			
DRONABINOL (ORAL)	0.2%	OFF	No-Generic			
CESAMET (ORAL)	0.0%	OFF	No			

- Discussion: None
- Brad Federly made a motion to accept staff recommendations as presented.
  - Second –Kevin Izard
  - All members were in favor of this motion.
  - Motion passes

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SYMLIN (SUBCUTANE.)	0.1%	OFF	No			
JANUVIA (ORAL)	75.8%	ON	Yes			
JANUMET (ORAL)	15.7%	ON	Yes			
ONGLYZA (ORAL)	1.5%	ON	Yes			
KOMBIGLYZE XR (ORAL)	0.0%	OFF	Yes			
BYETTA PENS (SUBCUTANE.)	6.1%	OFF	No	Place on Stat-PA		
SYMLIN PENS (SUBCUTANE.)	0.3%	OFF	No			
VICTOZA (SUBCUTANE.)	0.4%	OFF	No			

- Discussion: Dr Izard stated it is time to start addressing diabetes and obesity in the Medicaid population and using Byetta to treat Type 2 diabetes is a good place to start. Dr Izard stated that a step edit using metformin before using Byetta would be agreeable to him. Alicia Walker would like Byetta on STAT-PA.

Motion #1

- Pat Towers made a motion to accept staff recommendations as presented but place Byetta on STAT-PA.
  - Second – Alicia Walker
  - The vote was 7-1 in favor of this motion. Al Liegel was opposed.
  - Motion passes

Motion #2

- Brad Federly made a motion to accept recommendations as presented.
  - Second-Pat Towers
  - All members were in favor of the motion.
  - Motion passes

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HUMALOG MIX (SUBCUTANE.)	2.1%	ON	Yes			
HUMALOG (SUBCUTANE.)	17.3%	ON	Yes			
NOVOLIN PENS (SUBCUTANE.)	0.0%	OFF	No			
HUMULIN (SUBCUTANE.)	14.9%	ON	Yes			
NOVOLOG MIX 70/30 PENS	0.4%	OFF	No			

(SUBCUTANE.)						
NOVOLOG (SUBCUTANE.)	0.7%	OFF	No			
NOVOLIN (SUBCUTANE.)	0.2%	OFF	No			
NOVOLOG PENS (SUBCUTANE.)	1.0%	OFF	No			
LANTUS (SUBCUTANE.)	24.3%	ON	Yes			
NOVOLOG MIX 70/30 (SUBCUTANE.)	0.1%	OFF	No			
HUMALOG MIX PENS (SUBCUTANE.)	2.6%	ON	Yes			
HUMALOG PENS (SUBCUTANE.)	14.2%	ON	Yes			
LEVEMIR (SUBCUTANE.)	0.9%	OFF	No			
LANTUS PENS (SUBCUTANE.)	17.4%	ON	Yes			
LEVEMIR PENS (SUBCUTANE.)	1.4%	OFF	No			
APIDRA PENS (SUBCUTANE.)	0.1%	OFF	No			
APIDRA (SUBCUTANE.)	0.1%	OFF	No			
HUMULIN PENS (SUBCUTANE.)	2.4%	ON	Yes			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Roseanne Barber
  - All members were in favor of this motion.
  - Motion passes

<b>HYPOGLYCEMICS, MEGLITINIDES</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
PRANDIN (ORAL)	83.2%	ON	Yes			
PRANDIMET (ORAL)	0.2%	OFF	No			
NATEGLINIDE (ORAL)	16.6%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

HYPOGLYCEMICS, TZD						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AVANDARYL (ORAL)	0.5%	OFF	No			
ACTOS (ORAL)	79.2%	ON	Yes			
AVANDIA (ORAL)	10.5%	OFF	No			
ACTOPLUS MET (ORAL)	5.6%	ON	No			
AVANDAMET (ORAL)	3.7%	OFF	No			
DUETACT (ORAL)	0.5%	ON	No			
ACTOPLUS MET XR (ORAL)	0.0%	OFF	No			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Roseanne Barber
  - All members were in favor of this motion.
  - Motion passes

MULTIPLE SCLEROSIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AVONEX (INTRAMUSC.)	20.2%	OFF	Yes			
BETASERON (SUBCUTANE.)	13.8%	ON	Yes			
COPAXONE (SUBCUTANE.)	40.8%	ON	Yes			
REBIF (SUBCUTANE.)	23.7%	ON	Yes			
AMPYRA (ORAL)	1.3%	OFF	No			
EXTAVIA (SUBCUTANE.)	0.1%	OFF	No			
GILENYA (ORAL)	0.1%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second –James Boblin
  - All members were in favor of this motion.
  - Motion passes

LIPOTROPICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NIACOR (ORAL)	0.0%	ON	Yes			
GEMFIBROZIL (ORAL)	24.2%	ON	Yes-Generic			
ANTARA (ORAL)	0.1%	ON	No			
FENOFIBRIC ACID (ORAL)	0.0%	OFF	No-Generic			
TRICOR (ORAL)	18.8%	ON	Yes			
NIASPAN (ORAL)	21.4%	ON	Yes			
TRILIPIX (ORAL)	2.3%	ON	Yes			
ZETIA (ORAL)	7.3%	OFF	No	ON	OFF	
LIPOFEN (ORAL)	0.0%	OFF	No			
FENOFIBRATE (ORAL)	17.2%	ON	No-Generic			
COLESTIPOL (ORAL)	1.6%	ON	No-Generic			
WELCHOL (ORAL)	1.4%	OFF	No			
FENOGLIDE (ORAL)	0.0%	OFF	No			
LOVAZA (ORAL)	1.4%	ON	No			
CHOLESTYRAMINE (ORAL)	4.3%	ON	Yes-Generic			
FIBRICOR (ORAL)	0.0%	OFF	No			
TRIGLIDE (ORAL)	0.0%	OFF	No			

- Discussion: None

#### Motion #1

- Brad Fedderly made a motion to add Zetia to a preferred agent.
  - Second –Alicia Walker
  - The vote was 5-3 in favor of the motion. Al Liegel, Catherine Decker and Pat Towers were opposed.
  - Motion passes

#### Motion #2

- Brad Fedderly made a motion to accept remainder of staff recommendations as presented.
  - Second- Pat Towers
  - All members were in favor of this motion.
  - Motion passes

LIPOTROPICS, STATINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SIMVASTATIN (ORAL)	47.4%	ON	Yes-Generic			
LOVASTATIN (ORAL)	8.6%	ON	Yes-Generic			
PRAVASTATIN (ORAL)	7.2%	ON	Yes-Generic			

LESCOL / LESCOL XL (ORAL)	1.7%	ON	Yes			
CRESTOR (ORAL)	4.0%	OFF	Yes			
VYTORIN (ORAL)	10.5%	ON	No			
SIMCOR (ORAL)	0.3%	ON	No			
LIPITOR (ORAL)	20.1%	ON	Yes			
CADUET (ORAL)	0.1%	OFF	No			
ADVICOR (ORAL)	0.1%	OFF	No			
LIVALO (ORAL)	0.0%	OFF	No			
ALTOPREV (ORAL)	0.0%	OFF	No			

- Discussion: None

Motion #1

- Brad Fedderly made a motion to monitor availability and pricing of atorvastatin . When cost effective to the State make atorvastatin preferred.
  - Second –Pat Towers
  - All members were in favor of this motion.
  - Motion passes

- 
- Discussion: None

Motion #2

- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second--James Boblin
  - All members were in favor of this motion.
  - Motion passes

PLATELET AGGREGATION INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TICLOPIDINE (ORAL)	0.3%	OFF	No-Generic			
DIPYRIDAMOLE (ORAL)	0.6%	ON	Yes-Generic			
AGGRENOX (ORAL)	5.5%	ON	Yes			
PLAVIX (ORAL)	93.4%	ON	Yes			
EFFIENT (ORAL)	0.3%	OFF	No			

- Discussion: None

- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes
  -

ANTICOAGULANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WARFARIN (ORAL)	93.1%	ON	Yes-Generic			
PRADAXA (ORAL)	0.0%	OFF	No			
FRAGMIN (SUBCUTANE.)	1.0%	ON	Yes			
LOVENOX (SUBCUTANE.)	5.4%	OFF	Yes			
ARIXTRA (SUBCUTANE.)	0.2%	ON	Yes			
INNOHEP (SUBCUTANE.)	0.0%	OFF	No			
ENOXAPARIN (SUBCUTANE.)	0.3%	ON	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

ANDROGENIC AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ANDRODERM (TRANSDERM.)	19.5%	ON	Yes			
ANDROGEL (TRANSDERM.)	78.7%	ON	Yes			
FORTESTA (TRANSDERM)	0.1%	OFF	No			
TESTIM (TRANSDERM.)	1.7%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

BPH TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TERAZOSIN (ORAL)	15.9%	ON	Yes-Generic			
DOXAZOSIN (ORAL)	25.6%	ON	Yes-Generic			
UROXATRAL (ORAL)	3.1%	ON	Yes			

TAMSULOSIN (ORAL)	48.9%	ON	<b>Yes-Generic</b>			
FINASTERIDE (ORAL)	3.5%	ON	<b>Yes-Generic</b>			
CARDURA XL (ORAL)	0.0%	OFF	<b>No</b>			
AVODART (ORAL)	2.9%	OFF	<b>No</b>			
RAPAFLO (ORAL)	0.1%	OFF	<b>No</b>			
JALYN (ORAL)	0.0%	OFF	<b>No</b>			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

<b>PAH AGENTS, ORAL AND INHALED</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ADCIRCA (ORAL)	1.5%	OFF	<b>Yes</b>			
REVATIO (ORAL)	68.1%	ON	<b>No</b>	<b>GF</b>		
TRACLEER (ORAL)	20.7%	ON	<b>Yes</b>			
LETAIRIS (ORAL)	6.3%	ON	<b>No</b>	<b>ON</b>		
VENTAVIS (INHALATION)	1.2%	OFF	<b>Yes</b>			
TYVASO (INHALATION)	2.2%	OFF	<b>No</b>			

Discussion: Catherine Decker discussed Letairis remaining preferred due to robust safety data on liver function tests. Catherine Decker also discussed grandfathering members currently taking Revatio.

Motion #1

- Catherine Decker made a motion for Letairis to remain preferred.
  - Second-Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

Discussion: None

Motion #2

- Catherine Decker made a motion to grandfather members currently taking Revatio.
  - Second-Pat Towers
  - All members were in favor of this motion.
  - Motion passes

Discussion: None

Motion #3

- Catherine Decker made a motion to accept the remaining staff recommendations as presented.
  - Second- Brad Fedderly

- The vote was 7-1 in favor of the motion. Al Liegel was opposed.
- Motion passes

<b>BLADDER RELAXANT PREPARATIONS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
OXYBUTYNIN (ORAL)	37.1%	ON	<b>Yes-Generic</b>			
OXYTROL (TRANSDERM.)	0.5%	OFF	<b>No</b>			
TOVIAZ (ORAL)	0.9%	OFF	<b>Yes</b>			
VESICARE (ORAL)	39.3%	ON	<b>Yes</b>			
SANCTURA XR (ORAL)	0.7%	OFF	<b>No</b>			
DETROL (ORAL)	0.4%	OFF	<b>No</b>			
DETROL LA (ORAL)	5.8%	OFF	<b>No</b>			
ENABLEX (ORAL)	10.6%	ON	<b>No</b>			
GELNIQUE (TRANSDERM.)	0.2%	OFF	<b>No</b>			
OXYBUTYNIN ER (ORAL)	4.4%	OFF	<b>No-Generic</b>			
TROSPIMUM (ORAL)	0.1%	OFF	<b>No-Generic</b>			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - The vote was 7-1 in favor of this motion. Alicia Walker was opposed.
  - Motion passes

<b>BETA-BLOCKERS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ATENOLOL / CHLORTHALIDONE (ORAL)	25.5%	ON	<b>Yes-Generic</b>			
METOPROLOL / HCTZ (ORAL)	27.0%	ON	<b>Yes-Generic</b>			
CARVEDILOL (ORAL)	12.4%	ON	<b>Yes-Generic</b>			
PROPRANOLOL / HCTZ (ORAL)	4.7%	ON	<b>Yes-Generic</b>			
SOTALOL (ORAL)	0.8%	ON	<b>Yes-Generic</b>			
TOPROL XL (ORAL)	0.5%	OFF	<b>Yes</b>			
NADOLOL / BENDROFLUMETHIAZIDE (ORAL)	1.1%	ON	<b>Yes-Generic</b>			
LABETALOL (ORAL)	2.4%	ON	<b>Yes-Generic</b>			
ACEBUTOLOL (ORAL)	0.2%	ON	<b>Yes-Generic</b>			

PINDOLOL (ORAL)	0.1%	ON	Yes-Generic			
BISOPROLOL / HCTZ (ORAL)	1.4%	ON	Yes-Generic			
INNOPRAN XL (ORAL)	0.0%	ON	No			
TIMOLOL (ORAL)	0.0%	ON	Yes-Generic			
PROPRANOLOL ER (ORAL)	2.9%	ON	Yes-Generic			
LEVATOL (ORAL)	0.0%	OFF	No			
BYSTOLIC (ORAL)	0.9%	OFF	No			
METOPROLOL XL (ORAL)	19.8%	ON	No-Generic			
BETAXOLOL (ORAL)	0.0%	OFF	No-Generic			
COREG CR (ORAL)	0.1%	OFF	No			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

CALCIUM CHANNEL BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMLODIPINE (ORAL)	63.7%	ON	Yes-Generic			
NICARDIPINE (ORAL)	0.1%	ON	Yes-Generic			
VERAPAMIL (ORAL)	7.7%	ON	Yes-Generic			
DYNACIRC CR (ORAL)	0.1%	ON	Yes			
DILTIAZEM (ORAL)	19.0%	ON	Yes-Generic			
COVERA-HS (ORAL)	0.0%	OFF	No			
CARDENE SR (ORAL)	0.0%	OFF	No			
ISRADIPINE (ORAL)	0.1%	OFF	No-Generic			
FELODIPINE ER (ORAL)	1.4%	ON	No-Generic			
NIFEDIPINE ER (ORAL)	6.8%	ON	Yes-Generic			
NIFEDIPINE IR (ORAL)	0.4%	ON	No-Generic			
VERAPAMIL ER PM (ORAL)	0.2%	ON	No-Generic			
DILTIAZEM LA (ORAL)	0.4%	OFF	No-Generic			
NISOLDIPINE (ORAL)	0.1%	OFF	No-Generic			
NIMODIPINE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None

- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –Kevin Izard
  - All members were in favor of this motion.
  - Motion passes

ANGIOTENSIN MODULATOR COMBINATIIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EXFORGE / EXFORGE HCT (ORAL)	45.9%	ON	Yes			
AZOR / TRIBENZOR (ORAL)	36.4%	OFF	Yes			
VALTURNA (ORAL)	4.3%	ON	Yes			
TEKAMLO / AMTURNIDE (ORAL)	0.0%	OFF	No			
TWYNSTA (ORAL)	0.0%	OFF	No			
AMLODIPINE / BENAZEPRIL (ORAL)	13.3%	OFF	No-Generic			
TRANDOLAPRIL / VERAPAMIL (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

ANGIOTENSIN MODULATORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LOSARTAN / HCTZ (ORAL)	11.8%	ON	Yes-Generic			
ENALAPRIL / HCTZ (ORAL)	7.7%	ON	Yes-Generic			
CAPTOPRIL / HCTZ (ORAL)	0.9%	ON	Yes-Generic			
LISINOPRIL / HCTZ (ORAL)	51.8%	ON	Yes-Generic			
RAMIPRIL (ORAL)	0.6%	ON	Yes-Generic			
BENAZEPRIL / HCTZ (ORAL)	4.9%	ON	Yes-Generic			
QUINAPRIL / HCTZ (ORAL)	0.7%	ON	Yes-Generic			
DIOVAN / HCT (ORAL)	16.4%	OFF	Yes			
BENICAR / BENICAR HCT (ORAL)	1.0%	OFF	No			

TRANDOLAPRIL (ORAL)	0.1%	ON	No-Generic			
AVAPRO / AVALIDE (ORAL)	0.6%	OFF	No			
FOSINOPRIL / HCTZ (ORAL)	0.9%	ON	No-Generic			
MICARDIS / MICARDIS HCT (ORAL)	2.0%	OFF	No			
MOEXIPRIL / HCTZ (ORAL)	0.1%	OFF	No-Generic			
ATACAND / HCT (ORAL)	0.3%	OFF	No			
TEKTURNA / TEKTURNA HCT (ORAL)	0.3%	OFF	No			
TEVETEN / TEVETEN HCT (ORAL)	0.0%	OFF	No			
PERINDOPRIL (ORAL)	0.0%	ON	No-Generic			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

PROTON PUMP INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANTOPRAZOLE (ORAL)	2.1%	OFF	Yes-Generic			
ACIPHEX (ORAL)	16.8%	ON	Yes			
PRILOSEC SUSPENSION (ORAL)	0.0%	OFF	No			
DEXILANT (ORAL)	0.3%	OFF	No			
OMEPRAZOLE (ORAL)	74.1%	ON	Yes-Generic			
PROTONIX SUSPENSION (ORAL)	0.0%	OFF	No			
NEXIUM (ORAL)	4.1%	OFF	No			
NEXIUM SUSPENSION (ORAL)	0.0%	OFF	No			
LANSOPRAZOLE CAPSULES (ORAL)	2.4%	OFF	No-Generic			
LANSOPRAZOLE SOLUTAB (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None

- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

<b>ACNE AGENTS, TOPICAL</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
BENZAFLIN (TOPICAL)	0.2%	OFF	No			
ERYTHROMYCIN (TOPICAL)	5.8%	ON	Yes-Generic			
RETIN-A MICRO (TOPICAL)	0.0%	ON	Yes			
AZELEX (TOPICAL)	1.5%	ON	Yes			
CLINDAMYCIN PHOSPHATE (TOPICAL)	34.7%	ON	Yes-Generic			
AKNE-MYCIN (TOPICAL)	0.0%	OFF	No			
BENZOYL PEROXIDE (TOPICAL)	26.9%	ON	No-Generic	ON		
EPIDUO (TOPICAL)	0.2%	OFF	No			
CLINDAGEL (TOPICAL)	0.1%	OFF	No			
DIFFERIN (TOPICAL)	8.4%	OFF	Yes			
TRETINOIN (TOPICAL)	18.5%	ON	Yes-Generic			
NUOX (TOPICAL)	0.0%	OFF	No			
ACZONE (TOPICAL)	0.2%	OFF	No			
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	0.3%	OFF	No-Generic			
SULFACETAMIDE / SULFUR (TOPICAL)	0.2%	OFF	No-Generic			
CLINAC BPO (TOPICAL)	0.3%	ON	No			
EVOCLIN (TOPICAL)	0.0%	OFF	No			
TAZORAC (TOPICAL)	0.5%	OFF	No			
SULFACETAMIDE (TOPICAL)	0.1%	OFF	No-Generic			
ATRALIN (TOPICAL)	0.0%	OFF	No			
CLARIFOAM EF (TOPICAL)	0.0%	OFF	No			
ZIANA (TOPICAL)	0.0%	OFF	No			
ADAPALENE GEL (TOPICAL)	1.2%	ON	No-Generic			
ACANYA	0.0%	OFF	No			

(TOPICAL)						
CLINDAMYCIN / BENZOYL PEROXIDE (TOPICAL)	0.6%	OFF	No-Generic			
ADAPALENE CREAM (TOPICAL)	0.2%	ON	No-Generic			
VELTIN (TOPICAL)	0.0%	OFF	No			
SE BPO (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented with the addition of benzoyl peroxide.
  - Second –James Boblin
  - All members were in favor of this motion.
  - Motion passes

ANTIBIOTICS, GI						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METRONIDAZOLE (ORAL)	88.9%	ON	Yes-Generic			
NEOMYCIN (ORAL)	0.7%	ON	Yes-Generic			
TINDAMAX (ORAL)	7.1%	ON	Yes			
FLAGYL ER (ORAL)	0.0%	OFF	No			
VANCOCIN HCL (ORAL)	1.2%	ON	Yes			
ALINIA (ORAL)	1.2%	ON	Yes			
XIFAXAN (ORAL)	0.9%	OFF	No			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

ANTIBIOTICS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOBI (INHALATION)	92.0%	ON	Yes			
CAYSTON (INHALATION)	8.0%	OFF	No			

- Discussion: None

- Roseanne Barber made a motion to accept staff recommendations as presented.
  - Second –Catherine Decker
  - All members were in favor of this motion.
  - Motion passes

<b>ANTIBIOTICS, TOPICAL</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
GENTAMICIN SULFATE (TOPICAL)	2.6%	ON	<b>Yes-Generic</b>			
BACITRACIN (TOPICAL)	13.7%	ON	<b>Yes-Generic</b>			
BACITRACIN/POLYMYXIN (TOPICAL)	2.6%	ON	<b>Yes-Generic</b>			
MUPIROCIIN OINTMENT (TOPICAL)	80.9%	ON	<b>Yes-Generic</b>			
BACTROBAN CREAM (TOPICAL)	0.1%	OFF	<b>No</b>			
ALTABAX (TOPICAL)	0.2%	OFF	<b>No</b>			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
  - Second –Catherine Decker
  - All members were in favor of this motion.
  - Motion passes

<b>ANTIBIOTICS, VAGINAL</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
VANDAZOLE (VAGINAL)	8.9%	ON	<b>Yes</b>			
CLEOCIN OVULES (VAGINAL)	6.3%	OFF	<b>Yes</b>			
METRONIDAZOLE (VAGINAL)	76.3%	ON	<b>Yes-Generic</b>			
CLINDESSE (VAGINAL)	0.0%	OFF	<b>No</b>			
CLINDAMYCIN (VAGINAL)	8.5%	ON	<b>Yes-Generic</b>			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –Catherine Decker
  - All members were in favor of this motion.
  - Motion passes

CEPHALOSPORINS AND RELATED ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CEPHALEXIN (ORAL)	36.1%	ON	Yes-Generic			
CEFUROXIME (ORAL)	4.0%	ON	Yes-Generic			
AUGMENTIN 125 SUSPENSION (ORAL)	0.0%	ON	Yes			
AMOXICILLIN/CLAV TABLET (ORAL)	26.1%	ON	Yes-Generic			
SUPRAX (ORAL)	1.2%	ON	Yes			
CEFADROXIL (ORAL)	2.2%	ON	Yes-Generic			
AUGMENTIN 250 SUSPENSION (ORAL)	0.1%	OFF	Yes			
AMOXICILLIN/CLAV SUSPENSION (ORAL)	14.4%	ON	Yes-Generic			
CEFPROZIL (ORAL)	2.7%	ON	Yes-Generic			
CEDAX (ORAL)	0.0%	ON	No			
CEFDINIR (ORAL)	12.6%	ON	Yes-Generic			
CEFACTOR (ORAL)	0.1%	ON	Yes-Generic			
CEFPODOXIME (ORAL)	0.4%	OFF	No-Generic			
AMOXICILLIN/CLAV XR (ORAL)	0.0%	ON	No-Generic			
CEFDITOREN (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Roseanne Barber
  - All members were in favor of this motion.
  - Motion passes

FLUOROQUINOLONES, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CIPROFLOXACIN TABLETS (ORAL)	86.4%	ON	Yes-Generic			
NOROXIN (ORAL)	0.0%	OFF	No			
AVELOX (ORAL)	11.1%	ON	Yes			
LEVAQUIN (ORAL)	2.3%	OFF	No			
OFLOXACIN (ORAL)	0.0%	OFF	No-Generic			
FACTIVE (ORAL)	0.0%	OFF	No			
CIPRO SUSPENSION	0.2%	OFF	No			

(ORAL)						
CIPROFLOXACIN ER (ORAL)	0.0%	OFF	<b>No-Generic</b>			
PROQUIN XR (ORAL)	0.0%	OFF	<b>No</b>			

Discussion: Kevin Izard discussed when generic Levaquin becomes available and is cost effective; it should become a preferred product. Al Liegel discussed when generic Levaquin becomes preferred; Avelox should become non-preferred.

**Motion # 1**

- Kevin Izard made a motion to have generic Levaquin become preferred when available and cost effective, and change Avelox to non preferred at that time.
  - Second- Pat Towers
  - All members were in favor of this motion.
  - Motion passes

**Motion #2**

- Kevin Izard made a motion to accept the remaining staff recommendations as presented
  - Second-Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

<b>MACROLIDES-KETOLIDES</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ERYTHROMYCIN (ORAL)	1.1%	ON	<b>Yes-Generic</b>			
AZITHROMYCIN (ORAL)	95.2%	ON	<b>Yes-Generic</b>			
CLARITHROMYCIN (ORAL)	3.7%	ON	<b>Yes-Generic</b>			
ZMAX (ORAL)	0.0%	OFF	<b>No</b>			
KETEK (ORAL)	0.0%	OFF	<b>No</b>			
CLARITHROMYCIN ER (ORAL)	0.0%	OFF	<b>No-Generic</b>			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

<b>TETRACYCLINES</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
TETRACYCLINE (ORAL)	11.6%	ON	<b>Yes-Generic</b>			
DOXYCYCLINE	63.2%	ON	<b>Yes-Generic</b>			

HYCLATE (ORAL)						
MINOCYCLINE CAPSULES (ORAL)	20.0%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE (ORAL)	3.4%	OFF	No-Generic			
ORACEA (ORAL)	0.1%	OFF	No			
VIBRAMYCIN SUSPENSION (ORAL)	0.2%	OFF	No			
DOXYCYCLINE HYCLATE DR (ORAL)	0.0%	OFF	No-Generic			
MINOCYCLINE TABLETS (ORAL)	0.4%	OFF	No-Generic			
DORYX (ORAL)	0.8%	OFF	No			
ADOXA TT (ORAL)	0.0%	OFF	No			
DEMECLOCYCLINE (ORAL)	0.2%	OFF	No-Generic			
MINOCYCLINE ER (ORAL)	0.2%	OFF	No-Generic			
ADOXA CK (ORAL)	0.0%	OFF	No			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second –Roseanne Barber
  - All members were in favor of this motion.
  - Motion passes

ANTIFUNGALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUCONAZOLE (ORAL)	66.7%	ON	Yes-Generic			
KETOCONAZOLE (ORAL)	1.8%	ON	Yes-Generic			
TERBINAFINE (ORAL)	4.1%	ON	Yes-Generic			
GRIS-PEG (ORAL)	0.9%	ON	Yes			
NYSTATIN (ORAL)	20.8%	ON	Yes-Generic			
GRISEOFULVIN SUSPENSION (ORAL)	4.8%	ON	Yes-Generic			
GRIFULVIN V TABLETS (ORAL)	0.1%	OFF	No			
LAMISIL GRANULES (ORAL)	0.0%	OFF	No			
ORAVIG (BUCCAL)	0.0%	OFF	No			
SPORANOX SOLUTION (ORAL)	0.1%	OFF	No			

ANCOBON (ORAL)	0.0%	ON	No			
ITRACONAZOLE (ORAL)	0.4%	ON	Yes-Generic			
VFEND (ORAL)	0.3%	OFF	No			
VORICONAZOLE TABLETS (ORAL)	0.0%	OFF	No-Generic			
NOXAFIL (ORAL)	0.1%	OFF	No			

- Discussion: None
- Pat Tower made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

ANTIFUNGALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOLNAFTATE OTC (TOPICAL)	0.5%	ON	Yes-Generic			
NYSTATIN-TRIAMCINOLONE (TOPICAL)	6.6%	ON	Yes-Generic			
MICONAZOLE OTC (TOPICAL)	2.8%	ON	Yes-Generic			
NYSTATIN (TOPICAL)	34.7%	ON	Yes-Generic			
CICLOPIROX SOLUTION (TOPICAL)	0.2%	OFF	No-Generic			
CLOTTRIMAZOLE OTC (TOPICAL)	6.0%	ON	Yes-Generic			
CLOTTRIMAZOLE-BETAMETHASONE (TOPICAL)	12.5%	ON	Yes-Generic			
CLOTTRIMAZOLE RX (TOPICAL)	12.0%	ON	Yes-Generic			
ECONAZOLE (TOPICAL)	3.6%	OFF	No-Generic			
KETOCONAZOLE SHAMPOO (TOPICAL)	8.8%	ON	Yes-Generic			
OXISTAT (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE (TOPICAL)	12.1%	OFF	Yes-Generic			
NAFTIN (TOPICAL)	0.1%	OFF	No			
MENTAX (TOPICAL)	0.0%	OFF	No			
CICLOPIROX CR/SUSP/GEL (TOPICAL)	0.1%	OFF	No-Generic			
EXELDERM (TOPICAL)	0.0%	OFF	No			
VUSION (TOPICAL)	0.0%	OFF	No			
ERTACZO (TOPICAL)	0.0%	OFF	No			
XOLEGEL (TOPICAL)	0.0%	OFF	No			

LAMISIL SOLUTION (TOPICAL)	0.0%	OFF	No			
NUZOLE (TOPICAL)	0.0%	OFF	No			
CICLOPIROX SHAMPOO (TOPICAL)	0.0%	ON	No-Generic			
BENSAL HP (TOPICAL)	0.0%	OFF	No			
PEDIADERM AF (TOPICAL)	0.0%	OFF	No			
EXTINA (TOPICAL)	0.0%	OFF	No			
KETOCON + PLUS (TOPICAL)	0.0%	OFF	No			
CNL 8 (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second –Catherine Decker
  - All members were in favor of this motion.
  - Motion passes

ANTIVIRALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACYCLOVIR (ORAL)	31.5%	ON	Yes-Generic			
AMANTADINE (ORAL)	5.3%	ON	Yes-Generic			
RIMANTADINE (ORAL)	0.0%	ON	Yes-Generic			
RELENZA (INHALATION)	0.0%	ON	Yes			
TAMIFLU (ORAL)	0.5%	ON	Yes			
VALACYCLOVIR (ORAL)	60.7%	ON	Yes-Generic			
FAMCICLOVIR (ORAL)	2.0%	ON	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

ANTIVIRALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOVIRAX OINTMENT (TOPICAL)	70.5%	ON	Yes			
DENAVIR (TOPICAL)	27.0%	ON	Yes			
XERESE	0.1%	OFF	No			

(TOPICAL)						
ZOVIRAX CREAM (TOPICAL)	2.4%	OFF	No			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Pat Towers
  - All members were in favor of this motion.
  - Motion passes

<b>ANTIPARASITICS, TOPICAL</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
PERMETHRIN OTC (TOPICAL)	24.8%	ON	Yes-Generic			
PERMETHRIN (TOPICAL)	72.9%	ON	Yes-Generic			
EURAX (TOPICAL)	1.0%	OFF	No			
LINDANE (TOPICAL)	0.3%	OFF	No-Generic			
ULESFIA (TOPICAL)	0.3%	OFF	No			
MALATHION (TOPICAL)	0.7%	OFF	No-Generic			
NATROBA (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

<b>BONE RESORPTION SUPPRESSION AND RELATED AGENTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ALENDRONATE TABLETS (ORAL)	85.3%	ON	Yes-Generic			
MIACALCIN (NASAL)	3.5%	ON	Yes			
ACTONEL (ORAL)	3.3%	OFF	No			
EVISTA (ORAL)	3.6%	OFF	No			
BONIVA (ORAL)	3.0%	OFF	No			
FORTICAL (NASAL)	0.1%	OFF	No			
FOSAMAX PLUS	0.7%	OFF	No			

D (ORAL)						
FOSAMAX SOLUTION (ORAL)	0.1%	OFF	No			
ATELVIA (ORAL)	0.0%	OFF	No			
CALCITONIN SALMON (NASAL)	0.5%	OFF	No-Generic			
ETIDRONATE DISODIUM (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second –Kevin Izard
  - All members were in favor of this motion.
  - Motion passes

COLONY STIMULATING FACTORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NEUPOGEN (INJECTION)	66.5%	NR	Yes			
LEUKINE (INJECTION)	0.6%	NR	No			
NEULASTA (INJECTION)	32.9%	NR	No			

- Discussion: New class
- Catherine Decker made a motion to accept staff recommendations as presented.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

ERYTHROPOIESIS STIMULATING PROTEINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ARANESP (INJECTION)	33.1%	ON	Yes			
EPOGEN (INJECTION)	4.2%	OFF	No			
PROCRIT (INJECTION)	62.7%	ON	Yes			

- Discussion: None
- Al Liegel made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly

- All members were in favor of this motion.
- Motion passes

<b>GROWTH HORMONE</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
SAIZEN PENS (INJECTION)	0.0%	OFF	No			
SAIZEN VIALS (INJECTION)	0.0%	OFF	No			
TEV-TROPIN VIALS (INJECTION)	0.3%	OFF	No			
OMNITROPE PENS (INJECTION)	0.0%	OFF	No			
NUTROPIN VIALS (INJECTION)	2.9%	ON	Yes			
NUTROPIN AQ PENS (INJECTION)	22.8%	ON	Yes			
NUTROPIN AQ VIALS (INJECTION)	3.0%	ON	Yes			
NORDITROPIN PENS (INJECTION)	35.6%	ON	Yes			
GENOTROPIN PENS (INJECTION)	35.3%	ON	Yes			
OMNITROPE VIALS (INJECTION)	0.0%	OFF	No			
SEROSTIM VIALS (INJECTION)	0.0%	OFF	No			
NORDITROPIN VIALS (INJECTION)	0.0%	ON	Yes			
HUMATROPE PENS (INJECTION)	0.0%	OFF	No			
HUMATROPE VIALS (INJECTION)	0.0%	OFF	No			
ZORBTIVE VIALS (INJECTION)	0.0%	OFF	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second –Kevin Izard
  - All members were in favor of this motion.
  - Motion passes

HEPATITIS C AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RIBAVIRIN (ORAL)	44.8%	ON	Yes-Generic			
PEG-INTRON (SUBCUTANE.)	1.2%	ON	Yes			
PEGASYS (SUBCUTANE.)	36.9%	ON	Yes			
PEG-INTRON REDIPEN (SUBCUTANE.)	15.5%	ON	Yes			
INFERGEN (SUBCUTANE.)	1.6%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes

ULCERATIVE COLITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SULFASALAZINE (ORAL)	30.9%	ON	Yes-Generic			
ASACOL (ORAL)	46.0%	ON	Yes			
DIPENTUM (ORAL)	0.1%	OFF	No			
APRISO (ORAL)	1.8%	ON	Yes			
PENTASA (ORAL)	7.4%	OFF	No			
BALSALAZIDE (ORAL)	3.4%	ON	No-Generic	GF	ON	
LIALDA (ORAL)	3.4%	OFF	No			
CANASA (RECTAL)	1.8%	ON	Yes			
ASACOL HD (ORAL)	4.8%	ON	No	GF	OFF	
SFROWASA (RECTAL)	0.0%	OFF	No			
MESALAMINE (RECTAL)	0.3%	OFF	No-Generic			

Discussion: None

Motion #1

- Brad Fedderly made a motion to grandfather members on all medications changing to non preferred in this class
  - Second- Pat Towers
  - All members were in favor of this motion.
  - Motion passes

Discussion: None

Motion #2

- Brad Fedderly made a motion to accept the remaining staff recommendations as presented.
  - Second- Roseanne Barber
  - All members were in favor of this motion
  - Motion passes

PANCREATIC ENZYMES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANCRELIPASE (ORAL)	10.2%	ON	Yes-Generic			
ZENPEP (ORAL)	8.9%	ON	Yes			
CREON (ORAL)	74.8%	OFF	No			
PANCREAZE (ORAL)	6.1%	ON	No	GF		

- Discussion: Catherine Decker discussed concerns with Pancreaze becoming non-preferred. Zenpep will be the only preferred product appropriate for adult therapy. The ratio of the two products is not the same. Catherine also discussed concern with Cystic Fibrosis patients having to switch medications to align with hospital formularies. Prior Authorization could be obtained for the non preferred medication. Brad Fedderly commented that decisions made here will not influence hospital formulary decisions.
- Kevin Izard made a motion to accept staff recommendations as presented, but grandfather members currently taking Pancreaze.
  - Second- Pat Towers
  - The vote was 6-3 in favor of the motion. James Boblin, Catherine Decker and Ron Diamond were opposed.
  - Motion passes

PHOSPHATE BINDERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ELIPHOS (ORAL)	0.2%	OFF	Yes			
CALCIUM ACETATE (ORAL)	6.4%	ON	Yes-Generic			
FOSRENOL (ORAL)	14.2%	ON	Yes			
RENAGEL (ORAL)	66.7%	ON	Yes			
RENVELA (ORAL)	12.6%	OFF	No			

- Discussion: None
- Brad Fedderly made a motion to accept staff recommendations as presented.
  - Second –Al Liegel
  - All members were in favor of this motion.
  - Motion passes

<b>HIV - AIDS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
NORVIR CAPSULES (ORAL)	5.6%	NR	Yes			
RETROVIR (ORAL)	0.0%	NR	No	GF		
NORVIR TABLETS (ORAL)	10.1%	NR	Yes			
ZIDOVUDINE (ORAL)	1.4%	NR	Yes-Generic			
VIDEX (ORAL)	0.3%	NR	Yes			
STAVUDINE (ORAL)	0.3%	NR	Yes-Generic			
VIDEX EC (ORAL)	0.0%	NR	Yes			
EMTRIVA (ORAL)	0.6%	NR	Yes			
EPIVIR (ORAL)	1.4%	NR	Yes			
DIDANOSINE (ORAL)	0.4%	NR	Yes-Generic			
VIRAMUNE (ORAL)	2.1%	NR	Yes			
RESCRIPTOR (ORAL)	0.0%	NR	No	GF		
ZIAGEN (ORAL)	2.2%	NR	Yes			
VIREAD (ORAL)	4.2%	NR	Yes			
ZERIT (ORAL)	0.0%	NR	No	GF		
SUSTIVA (ORAL)	1.8%	NR	Yes			
CRIXIVAN (ORAL)	0.1%	NR	Yes			
INVIRASE (ORAL)	0.2%	NR	Yes			
COMBIVIR (ORAL)	2.4%	NR	Yes			
INTELENCE (ORAL)	1.7%	NR	No	GF		
EPZICOM (ORAL)	3.2%	NR	Yes			
TRUVADA (ORAL)	19.1%	NR	Yes			
KALETRA (ORAL)	5.9%	NR	Yes			
VIRACEPT (ORAL)	0.3%	NR	No	GF		
LEXIVA (ORAL)	0.7%	NR	Yes			
REYATAZ (ORAL)	9.9%	NR	Yes			
ISENTRESS (ORAL)	7.0%	NR	Yes			
PREZISTA (ORAL)	6.0%	NR	Yes			
SELZENTRY (ORAL)	0.5%	NR	No	GF		
TRIZIVIR (ORAL)	1.1%	NR	Yes			
APTIVUS (ORAL)	0.0%	NR	No	GF		

ATRIPLA (ORAL)	11.2%	NR	Yes			
FUZEON (INJECTION)	0.0%	NR	No	GF		

- Discussion: Pat Towers stated that because this has become a chronic disease, it is important to have a PDL class for these medications. Rick Pope stated Provider Synergies looked at the most current HIV clinical guidelines, and not financial indicators when making these recommendations. The State has provided these recommendations to and received input from the Department of Public Health. The State will also provide committee response to this class proposal to the Department of Public Health. Brad Fedderly asked if the State was able to respond to new information in this class between PA Committee meetings. The response was yes, changes can be made in a timely manner. Alicia Walker expressed concerned with the expiration of PA for members and timeliness of obtaining new PAs. Carrie Gray stated that these medications will part of the Expedited Emergency Supply policy. This allows providers to obtain an approval for an emergency supply via the STAT-PA system.
- Kevin Izard made a motion to accept staff recommendations as presented, but grandfather members currently taking medications recommended as non-preferred.
  - Second- Brad Fedderly
  - All members were in favor of this motion.
  - Motion passes